EDAP TMS S.A. (EDAP) – Globe Newswire
-
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Associ
-
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
-
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
-
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
-
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
-
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
-
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
-
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
-
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
-
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
-
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
-
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
-
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology
-
EDAP to Present at Piper Sandler’s 35th Annual Healthcare Conference
-
EDAP Announces Third Quarter 2023 Financial Results
-
EDAP to Present at the Jefferies London Healthcare Conference
-
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023
-
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference
-
EDAP Announces Second Quarter 2023 Financial Results
-
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023
-
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
-
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
-
EDAP to Present at the Jefferies Healthcare Conference
-
EDAP Announces First Quarter 2023 Financial Results
-
EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023
-
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
-
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
-
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
-
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
-
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
-
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
-
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
-
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
-
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
-
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
-
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
-
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
-
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
-
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
-
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
-
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
-
EDAP Announces Record Q4 US Focal One Placements
-
EDAP Announces Record Q4 US Focal One Placements
-
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
-
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
-
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
-
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
-
EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference
-
EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference
-
EDAP Reports Third Quarter 2022 Results
Back to EDAP Stock Lookup
